Trump to appeal tariff ruling, warns of economic consequences
Precigen (NASDAQ:PGEN) Inc’s stock reached a significant milestone, hitting a 52-week high at $4.05. This marks a notable achievement for the biotechnology company, reflecting investor confidence and positive market sentiment. With a market capitalization of $1.18 billion and a beta of 1.87, the company shows significant market sensitivity. According to InvestingPro analysis, technical indicators suggest the stock is currently in overbought territory. Over the past year, Precigen’s stock has experienced a remarkable increase, with a 1-year change of 240.95%. This surge can be attributed to the company’s strategic initiatives and advancements in its innovative biotechnology solutions. The new 52-week high underscores the momentum Precigen has gained in the market, positioning it as a standout performer in the sector. The company maintains strong liquidity with a current ratio of 2.71, indicating robust short-term financial health. InvestingPro subscribers have access to 14 additional key insights about Precigen’s current market position.
In other recent news, Precigen Inc. announced that the U.S. Food and Drug Administration (FDA) has granted full approval for PAPZIMEOS, marking it as the first and only approved treatment for adults with recurrent respiratory papillomatosis (RRP). This approval came two weeks ahead of the expected PDUFA action date, as disclosed during a company conference call. Following this development, H.C. Wainwright reiterated its Buy rating with a price target of $8.50, while Citizens JMP raised its price target from $6.00 to $8.00, maintaining a Market Outperform rating. Additionally, Precigen has signed a commercial supply agreement with Catalent (NYSE:CTLT) Maryland, Inc. for the manufacturing of PAPZIMEOS, effective August 13, 2025. The agreement specifies that Catalent will handle various services including analytical, development, processing, and validation for PAPZIMEOS. Cantor Fitzgerald has also reiterated its Overweight rating on Precigen, indicating a positive outlook despite recent stock volatility. The wholesale acquisition cost for a full treatment cycle of PAPZIMEOS is set at $460,000. These developments highlight significant progress for Precigen in the biotechnology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.